-
Mycobacterium
- Tuberculosis (Second line agent)
- Leprosy
- Fungal infections
- Pneumocystis carinii Pneumonia (second line agent)
- First line in certain autoimmune Bullous Conditions
- Synthetic derivative of di-amino-sulfone
- Antiinflammatory activity
- Interferes with Neutrophil adherence and chemotaxis and its oxidation damage via myeloperoxidase
- Antibacterial activity
- Combine with other agents
- Adult: 100 mg orally daily
- Child: 1 mg/kg (up to 100 mg) orally daily
- Pneumocystis jiroveci (PJP, off-label)
-
PCP Pneumonia prophylaxis
- Adult
- Dapsone 100 mg orally daily
- Child (age >=1 month)
- Dapsone 2 mg/kg (up to 100 mg) orally daily OR
- Dapsone 4 mg/kg/week (up to 200 mg) orally once weekly
- Adult
-
PCP Pneumonia treatment
- Dapsone 100 mg orally daily for 21 days
- Combine with other agents (e.g. trimethoprim 5 mg/kg orally three times daily)
- Nausea or Vomiting
- Peripheral Neuropathy (rare)
- Hepatotoxicity
- Blood dyscrasias
- Hemoglobin decreased (1-2 grams)
- Reticulocytes increased (2-12%)
- Hemolysis in G6PD Deficiency
- Methemoglobinemia
- Renal effects
- Proteinuria or Albuminuria
- Nephrotic Syndrome
- Skin effects
- Photosensitivity (Sunburn risk)
- Erythema Nodosum leprosum in Leprosy treatment (50%)
- Pregnancy Category C
- Unknown safety in Lactation
-
Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD)
- Screen for G6PD Deficiency before starting Dapsone
-
Complete Blood Count
- Obtain baseline and monthly for at least 6 months (then twice yearly) while on Dapsone
-
Liver Function Tests
- Obtain periodic levels
- Dapsone Tablet (DailyMed)